NEWS & EVENTS

July 13, 2021

Hillstream BioPharma Expands the Scientific Advisory Board with the Addition of Leading Innovator in the Study of Ferroptosis and Cancer, Scott Dixon, Ph.D.

Hillstream BioPharma Expands the Scientific Advisory Board with the Addition of Leading Innovator in the Study of Ferroptosis and Cancer, Scott Dixon, Ph.D. July 13, 2021 World leader in the study of iron mediated cell death (IMCD)/ferroptosis, a novel cell death pathway used by cancer cells especially in drug resistant tumors Bridgewater, NJ – July…
June 2, 2021

Hillstream BioPharma Announces Abstract at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting highlighting HSB-1216’s Effect in Triple Negative Breast Cancer (TNBC)

Hillstream BioPharma Announces Abstract at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting highlighting HSB-1216’s Effect in Triple Negative Breast Cancer (TNBC) June 2nd, 2021 HSB-1216 and a novel anthracycline, pirarubicin, combined and targeted using Quatramer shows synergistic effect in TNBC Bridgewater, NJ – June 2, 2021 – Hillstream BioPharma, Inc. (“Hillstream”) today…
March 11, 2021

Hillstream BioPharma Adds Leading Cancer Drug Development Executive and Features Hillstream’s Quatramer-Based Ferroptosis Inducer, HSB-1216, in Two Abstracts Available for Viewing at AACR 2021 Annual Meeting

Hillstream BioPharma Adds Leading Cancer Drug Development Executive and Features Hillstream’s Quatramer-Based Ferroptosis Inducer, HSB-1216, in Two Abstracts Available for Viewing at AACR 2021 Annual Meeting March 11th, 2021 Lynne A. Bui M.D., leading cancer drug development executive, joins Hillstream BioPharma’s Board of Directors  Abstracts highlight mechanistic and pharmacokinetic data from HSB-1216 in small cell…
February 25, 2021

Hillstream BioPharma Announces Two Abstracts Accepted for Presentation at AACR 2021 Annual Meeting

Hillstream BioPharma Announces Two Abstracts Accepted for Presentation at AACR 2021 Annual Meeting February 25th, 2021 Abstracts highlight data from HSB-1216 in small cell lung cancer and in combination with low-dose chemotherapy in triple negative breast cancer Bridgewater, NJ – February 25, 2021 – Hillstream BioPharma, Inc. (“Hillstream”) today announced that two abstracts highlighting the…
January 11, 2021

Hillstream Selected to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright

Hillstream Selected to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright January 11th, 2021 Bridgewater, New Jersey - Hillstream BioPharma, Inc. (“Hillstream”), a clinical- stage biotechnology company leveraging its computational intelligence platform to help identify and develop novel therapeutics for rare cancers, announced today that the company will present at the 2021…
November 23, 2020

Hillstream BioPharma’s HSB-888 Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Osteosarcoma

Hillstream BioPharma’s HSB-888 Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Osteosarcoma November 23rd, 2020 Osteosarcoma remains the most common primary pediatric bone malignancy mostly occurring in adolescents for which treatment has remained essentially unchanged for the past three decades  Osteosarcoma is a highly-aggressive tumor with metastatic disease either at diagnosis or at…
November 18, 2020

Hillstream BioPharma Announces Richard M. Stone, MD as New Member to Scientific Advisory Board

Hillstream BioPharma Announces Richard M. Stone, MD as New Member to Scientific Advisory Board November 18th, 2020 Hillstream BioPharma Announces Richard M. Stone, MD as New Member to Scientific Advisory Board Expertise in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) Bridgewater, New Jersey, November 18, 2020 – Hillstream BioPharma, Inc. (“Hillstream”) today announced…
November 2, 2020

Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of Quatramer™ Technology with HDAC6-PI3Kδ Dual Inhibitor for AML

Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of Quatramer™ Technology with HDAC6-PI3Kδ Dual Inhibitor for AML November 2nd, 2020 Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of Quatramer™ Technology with HDAC6-PI3Kδ Dual Inhibitor for AML Bridgewater, NJ – November…
October 21, 2020

Hillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020

Hillstream BioPharma Completes Pre-IND Review with FDA on HSB-1216 for Small Cell Lung Cancer (SCLC) October 1st, 2020  Bridgewater, New Jersey, October 21, 2020 – Hillstream BioPharma Inc. (“Hillstream”, the “Company”), a clinical-stage pharmaceutical company, announced that it has successfully completed a pre-Investigational New Drug (IND) review citing a written response from the U.S. Food…
October 5, 2020

Hillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020

HillstreaHillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020 October 1st, 2020 Hillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020 Bridgewater, New Jersey, October 5, 2020 – Hillstream BioPharma, Inc. (“Hillstream”) today announced its participation in the Rare…
October 1, 2020

Hillstream BioPharma to Present at the Tenth Annual BioNJ BioPartnering Virtual Conference

Hillstream BioPharma to Present at the Tenth Annual BioNJ BioPartnering Virtual Conference October 1st, 2020 Hillstream BioPharma to Present at the Tenth Annual BioNJ BioPartnering Virtual Conference Bridgewater, New Jersey, October 1, 2020 – Hillstream BioPharma Inc. (“Hillstream”) today announced its participation at the Tenth Annual BioNJ BioPartnering Virtual Conference.  Hillstream will be providing updates…
August 17, 2020

Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020

Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020 August 17th, 2020 Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020  Chester, New Jersey, August 17, 2020 – Hillstream BioPharma Inc. (“Hillstream”) today announced its participation in the World Orphan Drug Conference USA.  Hillstream will be providing updates on…
May 19, 2020

Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II

Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II FEBRUARY 10, 2020 Abstracts highlight data from HSB-1216 (Salinomycin QUATRAMER™) in small cell lung cancer and triple negative breast cancer Chester, NJ – May 19, 2020 – Hillstream BioPharma, Inc. (“Hillstream”) today announced that two abstracts highlighting the progress of HSB-1216 (salinomycin QUATRAMER™) preclinical programs…
February 10, 2020

Hillstream BioPharma Acquires Novel Salinomycin-Analogs

Hillstream BioPharma Acquires Novel Salinomycin-Analogs FEBRUARY 10, 2020 Emerging Mechanism of Action: Ferroptosis – Strengthens Company’s Oncology Pipeline Chester, New Jersey, February 10, 2020 – Hillstream BioPharma Inc. (“Hillstream”), a near-clinical stage biotechnology company focused on rare, orphan and unmet need cancers announced today, acquisition of a salinomycin analogue portfolio with related global patents, non-clinical data, other…
February 3, 2020

Hillstream BioPharma to Present at Noble Capital’s Sixteenth Small and Micro Cap Conference

Hillstream BioPharma to Present at Noble Capital’s Sixteenth Small and Micro Cap Conference FEBRUARY 3, 2020 Chester, New Jersey, February 3, 2020 – Hillstream BioPharma Inc. (“Hillstream”) today announced its participation in Noble Capital’s Sixteenth Small and Micro Cap Conference.  Hillstream will be providing updates on recent corporate developments as well as outlining near-term activities anticipated in 1H-2020.  Details about…
January 6, 2020

Hillstream BioPharma Granted Orphan Drug Designation for HSB-1216 (QUATRAMER Salinomycin) for Treatment of Small Cell Lung Cancer (SCLC)

Hillstream BioPharma Granted Orphan Drug Designation for HSB-1216 (QUATRAMER Salinomycin) for Treatment of Small Cell Lung Cancer (SCLC) January 6, 2020 Positive pre-clinical data with an emerging validated mechanism of action, Ferroptosis HSB-1216 is a novel therapeutic using the QUARTRAMER formulation of a potent anti-Ferroptotic compounds, Salinomycin Chester, New Jersey, January 6, 2020 – Hillstream BioPharma…
January 2, 2020

Hillstream BioPharma Announces Participation in the Biotech Showcase’s PartneringOne® System and Availability for Outside Appointments

Hillstream BioPharma Announces Participation in the Biotech Showcase’s PartneringOne® System and Availability for Outside Appointments January 2, 2020 Chester, New Jersey, January 2, 2020 – Hillstream BioPharma Inc. (“Hillstream”) today announced its participation in the Biotech Showcase™’s one-to-one meeting system, partneringOne®.  The event will run from January 13-16, 2020.  One-on-one meetings booked through the partneringONE® system will be held…
December 3, 2019

Hillstream BioPharma to Present at the 12th Annual LDMicro 12th Main Event

Hillstream BioPharma to Present at the 12th Annual LDMicro 12th Main Event December 3, 2019 Chester, NJ – December 3, 2019 — Hillstream BioPharma Inc. (“Hillstream”) today announced that Chief Executive Officer, Randy Milby, will be presenting and meeting with investors at the 12th Annual LD Micro Annual Main Event Conference being held December 10-12,…
November 19, 2019

Hillstream BioPharma Announces Kwok-Kin Wong, MD, PhD as New Member to Scientific Advisory Board

Hillstream BioPharma Announces Kwok-Kin Wong, MD, PhD as New Member to Scientific Advisory Board November 19, 2019 Expertise in Small Cell Lung Cancer Supports Key Pipeline Drug – HSB: 1216 Chester, New Jersey, November 19, 2019 – Hillstream BioPharma Inc. (“Hillstream”) today announced the addition of clinician-scientist Kwok-Kin Wong, MD, PhD to Hillstream’s Scientific Advisory…
November 4, 2019

Hillstream BioPharma Announces Collaboration with Ardena to Support QUATRAMER Manufacturing

Hillstream BioPharma Announces Collaboration with Ardena to Support QUATRAMER Manufacturing November 4, 2019 Alignment Reinforces Hillstream BioPharma’s Strategy to Partner with Top-Tier Firms Chester, NJ – November 4, 2019 – Hillstream BioPharma, Inc. (“Hillstream”) today announced a collaboration with Ardena to secure manufacturing feasibility and capacity for Hillstream’s QUATRAMER portfolio. This includes HSB-1216, a novel…